SEC Form 4 · accession 0000899243-17-025437
Eledon Pharmaceuticals, Inc. · ELDN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Catherine C. Turkel
Officer — President
Period of report
Nov 6, 2017
Accepted (ET)
Nov 6, 2017 · 5:10 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001404281
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $4.21 | Nov 6, 2017 | A | 50,000 | A | — | Nov 6, 2027 | Common Stock | 50,000 | 50,000 | D |
Explanation of responses
- F1This option represents a right to purchase a total of 50,000 shares of the Issuer's Common Stock one quarter of which will become fully vested and exercisable on 11/6/2018, with the remaining 37,500 shares vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date.